Results 111 to 120 of about 203,299 (265)
ABSTRACT Hepatocellular carcinoma (HCC) remains a significant clinical challenge due to the limited efficacy of conventional treatments like surgery, radiofrequency ablation (RFA), and transarterial embolization (TAE). Here, we develop an innovative TAE and immunothermal therapy strategy based on smartly assembled near‐micron layered double hydroxide ...
Qitao Hu +12 more
wiley +1 more source
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr +19 more
wiley +1 more source
Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy
Engineered microparticles co‐delivering geldanamycin and dual nanobodies induce targeted pyroptosis and block PD‐L1 and CD47 pathways, reprogramming the tumor microenvironment and achieving potent antitumor immunity in lung cancer models with minimal toxicity.
Tianli Hao +12 more
wiley +1 more source
Bilateral Breast Fibroadenoma With Bilateral Ductal Carcinoma In Situ: A Case Report. [PDF]
Wang S, Zhang X, Tian W.
europepmc +1 more source
ABSTRACT Blood‐based liquid biopsies hold transformative potential for non‐invasive cancer management, but current approaches relying on rare circulating tumor components limit their broad clinical utility. Platelets, abundant in blood and mediating diverse cancer‐associated responses, represent a compelling yet largely unexplored alternative.
Yan Ma +28 more
wiley +1 more source
Nipple-Originating Solid Papillary Carcinoma In Situ: A Case Report and Literature Review. [PDF]
Yang Y, Hao X, Zhai Y, Xie X, Ma X.
europepmc +1 more source
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
Development and Validation of an Algorithm to Achieve Complete Registration of Danish Patients with Carcinoma In Situ of the Breast, 2008-2023. [PDF]
Simonsen MK +5 more
europepmc +1 more source
SpaMode introduces a versatile framework for spatial multi‐omics integration across vertical, horizontal, and mosaic scenarios. By disentangling modality‐invariant and variant features through a mixture‐of‐experts mechanism, it adaptively reconfigures spatially heterogeneous signals.
Xubin Zheng +6 more
wiley +1 more source
Trends in Nonsurgical Management for Low-Risk, Hormone Receptor-Positive Ductal Carcinoma In Situ. [PDF]
Matsui Y +6 more
europepmc +1 more source

